REPL250117C10000
- 6.50
- 0.000.00%
Replimune Newsroom
Replimune Group Is Maintained at Outperform by BMO Capital
H.C. Wainwright Maintains Replimune(REPL.US) With Buy Rating, Raises Target Price to $21
Express News | Replimune Group, Inc. : H.c. Wainwright Raises Target Price to $21 From $17
BMO Capital Maintains Replimune(REPL.US) With Buy Rating, Raises Target Price to $27
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Replimune's BLA For RP1-Nivolumab Combo Gets FDA Approval For Advanced Melanoma, Stock Surges
Express News | Replimune Group Inc - FDA Grants Priority Review for Replimune's Bla With Pdufa Date July 22, 2025
Express News | Replimune Announces Biologics License Application Acceptance and Priority Review for Rp1 for the Treatment of Advanced Melanoma
Barclays Maintains Replimune(REPL.US) With Buy Rating, Maintains Target Price $17
BMO Capital Maintains Replimune(REPL.US) With Buy Rating, Maintains Target Price $18
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Replimune Begins RP2 Clinical Trials With First Patients Enrolled In Metastatic Uveal Melanoma And Hepatocellular Carcinoma
Express News | Replimune Group Inc - Primary Endpoints of Rp2-202 Study Are Overall Survival and Progression Free Survival
Replimune to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Analysts Are Bullish on These Healthcare Stocks: Inovio Pharmaceuticals (INO), Replimune Group (REPL)
Jefferies Maintains Buy on Replimune Group, Raises Price Target to $19
Replimune Group Analyst Ratings
Express News | Replimune Shares Extend Gains; Last up 8%
Express News | Replimune Group Inc - Amendment Reduces Atm Offering to $89 Mln